Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2018

View Archived Issues

FDA accepts SIGA Technologies' NDA for TPOXX

Daiichi Sankyo studies DS-1205c with osimertinib for metastatic or unresectable EGFR-mutant NSCLC

New phase II umbrella trial studies novel agents for the management of relapsed ovarian cancer

V ClinBio acquires 49.98% equity stake in Cellix Bio

Rebinyn launched in the U.S.for the treatment of hemophilia B

Sanofi files tender offer for Bioverativ

Columbia University divulges novel CKI-epsilon inhibitors

Q Biomed receives exclusive option for glaucoma biomarker GDF-15

FDA priority review granted for antimalarial tafenoquine

New RET kinase inhibitors identified at Blueprint Medicines

Roche discovers new serine protease HTRA1 inhibitors

Shanghai Yingli Pharmaceutical presents new TGF-beta receptor type-1 inhibitors

Novel ACKR3 antagonists patented by Idorsia Pharmaceuticals

Therapix Biosciences clarifies regulatory pathway for THX-110

ABAC Therapeutics identifies novel antibacterials

AstraZeneca announces pipeline highlights of fourth quarter 2017

SPK-8011 shown safe and effective for hemophilia A

GlaxoSmithKline reviews milestones of fourth quarter 2017

Implantable device allows photodynamic therapy for tumors deep in the body

Vifor prepares to begin phase I trial of oral ferroportin inhibitor VIT-2763

Significant reductions in LDL-cholesterol seen with MGL-3196 in phase II tiral

uniQure presents further clinical data on AMT-060 for hemophilia B

Rexahn Pharmaceuticals to collaborate with Zhejiang Haichang Biotechnology on RX-0201

Lonza Pharma & Biotech and Denali Therapeutics partner on biologics

Bristol-Myers Squibb offers overview of fourth quarter 2017

FDA grants orphan drug designation to Xeris' ready-to-use, liquid-stable glucagon

Phase III trials of peficitinib in rheumatoid arthritis meet primary endpoints

Fujifilm and Takeda establish regenerative medicine collaboration to treat heart failure

Treatment begins in phase II SHINE-1 study of scar reduction with EB-001

FDA approves Zytiga with prednisone for metastatic high-risk castration-sensitive prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...